Recent advances in chronotherapy for the management of asthma

References

• Royal College of Physicians. Why asthma still kills: the National Review of Asthma Deaths (NRAD) Confidential Enquiry report. London, UK: RCP, 2014.
   Google Scholar
• Asthma UK. 2014. Available from: http://www.asthma.org.uk.
   Google Scholar
• Martinez FD, Vercelli D. Asthma. Lancet. 2013;382:1360–1372.
   PubMed Web of Science ®Google Scholar
• Hogg JC. Pathology of asthma. J Allergy Clin Immunol. 1993;92:1–5.
   PubMed Web of Science ®Google Scholar
• Bentley AM, Maestrelli P, Saetta M, et al. Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma. J Allergy Clin Immunol. 1992;89:821–829.
   PubMed Web of Science ®Google Scholar
• Bentley AM, Meng Q, Robinson DS, Hamid Q, Kay AB, Durham SR. Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol. 1993;8:35–42.
   PubMed Web of Science ®Google Scholar
• Bradley BL, Azzawi M, Jacobson M, et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol. 1991;88:661–674.
   PubMed Web of Science ®Google Scholar
• Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol. 2004;22:789–815.
   PubMed Web of Science ®Google Scholar
• van Oosterhout AJ, Bloksma N. Regulatory T-lymphocytes in asthma. Eur Respir J. 2995;26:918–932.
   Google Scholar
• Umetsu DT, Akbari O, Dekruyff RH. Regulatory T cells control the development of allergic disease and asthma. J Allergy Clin Immunol. 2003;112:480–487.
   PubMed Web of Science ®Google Scholar
• Larche M. Regulatory T cells in allergy and asthma. Chest. 2007;132:1007–1014.
   PubMed Web of Science ®Google Scholar
• McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol. 2008;181:4089–4097.
   PubMed Web of Science ®Google Scholar
• Kim HY, Lee HJ, Chang YJ, et al. Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med. 2014;20:54–61.
   PubMed Web of Science ®Google Scholar
• Yu X, Rollins D, Ruhn KA, et al. TH17 Cell differentiation is regulated by the circadian clock. Science. 2013;342:727–730.
   PubMed Web of Science ®Google Scholar
• Holgate ST. Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches? J Allergy Clin Immunol. 2011;128:495–505.
   PubMed Web of Science ®Google Scholar
• National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma, Publication No 97-4051. Bethesda, MD: US Department of Health and Human Services; 1997.
   Google Scholar
• Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–224.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–395.
   PubMed Web of Science ®Google Scholar
• Dougherty RH, Sidhu SS, Raman K, et al. Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma. J Allergy Clin Immunol. 2010;125:1046–1053.
   PubMed Web of Science ®Google Scholar
• Thomson NC, Patel M, Smith AD. Lebrikizumab in the personalized management of asthma. Biologics. 2012;6:329–335.
   PubMedGoogle Scholar
• Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088–1098.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–2466.
   PubMed Web of Science ®Google Scholar
• Cochrane GM, Clark TJH. A survey of asthma mortality in patients between ages 35 and 64 in Greater London Hospitals in 1971. Thorax. 1975;30:300–305.
   PubMed Web of Science ®Google Scholar
• Turner-Warwick M. Epidemiology of nocturnal asthma. Am J Med. 1988;85:6–8.
   PubMed Web of Science ®Google Scholar
• Sutherland ER. Nocturnal asthma. J Allergy Clin Immunol. 2005;6:1179–1186.
   Google Scholar
• Kraft M, Martin RJ, Wilson S, Djukanovic R, Holgate ST. Lymphocyte and eosinophil influx into alveolar tissue in nocturnal asthma. Am J Respir Crit Care Med. 1999;159:228–234.
   PubMed Web of Science ®Google Scholar
• Kelly EA, Houtman JJ, Jarjour NN. Inflammatory changes associated with circadian variation in pulmonary function in subjects with mild asthma. Clin Exp Allergy. 2004;34:227–233.
   PubMed Web of Science ®Google Scholar
• Trebble PJ, Woolven JM, Saunders KA, et al. A ligand-specific kinetic switch regulates glucocorticoid receptor trafficking and function. J Cell Sci. 2013;15:3159–3169.
   Google Scholar
• Trump RP, Bresciani S, Cooper AW, et al. Optimized chemical probes for REV-ERBα. J Med Chem. 2013;56(11):4729–4737.
   Web of Science ®Google Scholar
• Gibbs JE, Beesley S, Plumb L, et al. Circadian timing in the lung; a specific role of bronchiolar epithelial cells. Endocrinology. 2009;150:268–276.
   PubMed Web of Science ®Google Scholar
• Hadden H, Soldin SJ, Massaro D. Circadian disruption alters mouse lung clock gene expression and lung mechanics. J Appl Physiol. 2012;113:385–392.
   Web of Science ®Google Scholar
• Sukumaran S, Jusko WJ, DuBois DC, Almon RR. Light-dark oscillations in the lung transcriptome: implications for lung homeostasis, repair, metabolism, disease and drug action. J Appl Physiol. 2011;110:1732–1747.
   Web of Science ®Google Scholar
• Gibbs JE, Blaikley J, Beesley S, et al. The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. Proc Natl Acad Sci U S A. 2012;109:582–587.
   PubMed Web of Science ®Google Scholar
• Silver AC, Arjona A, Walker WE, Fikrig E. The circadian clock controls toll-like receptor 9-mediated innate and adaptive immunity. Immunity. 2012;36:251–261.
   PubMed Web of Science ®Google Scholar
• British Thoracic Society and Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax. 2014:69 (Suppl 1).
   Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373.
   PubMed Web of Science ®Google Scholar
• Maneechotesuwan K, Essilfie-Quaye S, Meah S, et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest. 2005;128:1936–1942.
   PubMed Web of Science ®Google Scholar
• Barnes P, FitzGerald G, Brown M, Dollery C. Nocturnal asthma and changes in circulating epinephrine, histamine and cortisol. N Engl J Med. 1980;303:263–267.
   PubMed Web of Science ®Google Scholar
• Takata M, Burioka N, Ohdo S, et al. β2-adrenoceptor agonists induce the mammalian clock gene hPer1 mRNA in cultured human bronchial epithelium cells in vitro. Chronobiol Int. 2005;22:777–783.
   PubMed Web of Science ®Google Scholar
• Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST. Protection against allergen-induced asthma by salmeterol. Lancet. 1990;336:1338–1342.
   PubMed Web of Science ®Google Scholar
• Postma DS, Koëter GH, Keyzer JJ, Meurs H. Influence of slow-release terbutaline on the circadian variation of catecholamines, histamine, and lung function in nonallergic patients with partly reversible airflow obstruction. J Allergy Clin Immunol. 1986;77:471–477.
   PubMed Web of Science ®Google Scholar
• Koëter GH, Postma DS, Keyzer JJ, Meurs H. Effect of oral slow-release terbutaline on early morning dyspnoea. Eur J Clin Pharmacol. 1985;28:159–162.
   PubMed Web of Science ®Google Scholar
• Dahl R, Harving H, Säwedal L, Anehus S. Terbutaline sustained-release tablets in nocturnal asthma – a placebo-controlled comparison between a high and a low evening dose. Br J Dis Chest. 1988;82:237–241.
   Google Scholar
• Arvidsson P, Larsson S, Löfdahl CG, Melander B, Svedmyr N, Wåhlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J. 1991;4:1168–1173.
   PubMed Web of Science ®Google Scholar
• Kesten S, Chapman KR, Broder I, et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann Allergy. 1992;69:415–420.
   PubMedGoogle Scholar
• Ball DI, Brittain RT, Coleman RA, et al. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo. Br J Pharmacol. 1991;104:665–671.
   PubMed Web of Science ®Google Scholar
• Brambilla C, Chastang C, Georges D, Bertin L. Salmeterol compared with slow-release terbutaline in nocturnal asthma. Allergy. 1994;49:421–426.
   PubMed Web of Science ®Google Scholar
• Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol and salbutamol in asthmatic patients. Eur Respir J. 1992;5:1062–1067.
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Rathner P, Rennard SI. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA. 1994;271:1412–1416.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick MF, Mackay T, Driver H, Douglas NJ. Salmeterol in nocturnal asthma: a double-blind, placebo controlled trial of a long acting inhaled β2 agonist. Br Med J. 1990;301:1365–1368.
   PubMedGoogle Scholar
• Lundback B, Rawlinson DW, Palmer JBD. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. Thorax. 1993;48:148–153.
   PubMed Web of Science ®Google Scholar
• Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992;327:1420–1425.
   PubMed Web of Science ®Google Scholar
• Ullman J, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. Am Rev Respir Dis. 1990;142:571–575.
   PubMedGoogle Scholar
• LaForce C, Korenblat P, Osborne P, Dong F, Higgins M. 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. Curr Med Res Opin. 2009;25(10):2353–2359.
   PubMed Web of Science ®Google Scholar
• Kempsford RD, Oliver A, Bal J, Tombs L, Quinn D. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respir Med. 2013;107(12):1873–1880.
   PubMed Web of Science ®Google Scholar
• The Global Initiative for Asthma (GINA) Report, Global Strategy for Asthma Management and Prevention, Evidence-Based Guidelines for Asthma Management and Prevention. Updated Dec 2008.
   Google Scholar
• Smolensky MH, Lemmer AE, Reinberg AE. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Adv Drug Deliv Rev. 2007;59:852–882.
   PubMed Web of Science ®Google Scholar
• Bando H, Nishio T, van der Horst GT, Masubuchi S, Hisa Y, Okamura H. Vagal regulation of respiratory clocks in mice. J Neurosci. 2007;27:4359–4365.
   PubMed Web of Science ®Google Scholar
• Coe CI, Barnes PJ. Reduction of nocturnal asthma by an inhaled anticholinergic drug. Chest. 1986;90:485–488.
   PubMed Web of Science ®Google Scholar
• Morrison JFJ, Pearson SB, Dean HG. Parasympathetic nervous system in nocturnal asthma. Br Med J. 1988;296:1427–1429.
   PubMed Web of Science ®Google Scholar
• Gaultier C, Reinberg A, Girard F. Circadian changes in lung resistance and dynamic compliance in healthy and asthmatic children. Effects of two bronchodilators. Respir Physiol. 1975;31:169–182.
   Google Scholar
• Peters SP, Kunselman SJ, Icitovic N, et al. National heart, lung, and blood institute asthma clinical research network. Tiotropium step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010;363:1715–1726.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003;58:855–860.
   PubMed Web of Science ®Google Scholar
• Ceresa F, Angeli G, Buccuzzi G, Molino G. Once-a-day neutrally stimulated and basal ACTH secretion phases in man and their response to corticoid inhibition. J Clin Endocrinol. 1969;29:1074–1082.
   Web of Science ®Google Scholar
• Beam WR, Weiner DE, Martin RJ. Timing of prednisolone and alteration of airways inflammation in nocturnal asthma. Am Rev Respir Dis. 1992;146:1524–1530.
   PubMedGoogle Scholar
• Reinberg A, Halberg F, Falliers C. Circadian timing of methylprednisolone effects in asthmatic boys. Chronobiologia. 1974;1:333–347.
   PubMedGoogle Scholar
• Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med. 1998; 157(3 pt 2):S1–S53.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Pedersen S, Busse WW, et al. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest. 2006;129:1478–1485.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis. 1990;40:S70–S76.
   Google Scholar
• Barnes PJ. Inhales glucocorticoids for asthma. N Engl J Med. 1995;332:868–875.
   PubMed Web of Science ®Google Scholar
• Pincus DJ, Szefler SJ, Ackerson LM, Martin RJ. Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol. 1995;95:1172–1178.
   PubMed Web of Science ®Google Scholar
• Pincus DJ, Humeston TR, Martin RJ. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol. 1997;100:771–774.
   PubMed Web of Science ®Google Scholar
• Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther. 2006;18:390–396.
   Web of Science ®Google Scholar
• Postma DS, Sevette C, Martinat Y, Schlosser N, Aumann J, Kafe J. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J. 2001;17:1083–1088.
   PubMed Web of Science ®Google Scholar
• Buhl R, Vinkler I, Maygar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther. 2005;19:404–412.
   Web of Science ®Google Scholar
• Kidney JC, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline iin asthma. Demonstration by withdrawing of therapy. Am J Respir Care Med. 1995; 151:1907–1914.
   PubMedGoogle Scholar
• Sullivan P, Songul B, Jaffar Z, Page C, Jeffery P, Costello J. Antiinflammatory effects of low dose oral theophylline in atopic asthma. Lancet. 1994;343:1006–1008.
   PubMed Web of Science ®Google Scholar
• Darow P, Steinijans VW. Therapeutic advantage of unequal dosing of theophylline in patients with nocturnal asthma. Chronobiol Int. 1987;4:349–357.
   Web of Science ®Google Scholar
• D’Alonzo GE, Smolensky MH, Feldman S, et al. Twenty-four hour lung function in adult patients with asthma. Chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing. Am Rev Respir Dis. 1990;142:84–90.
   PubMed Web of Science ®Google Scholar
• Kemp JP. Recent advances in the management of asthma using leukotriene modifiers. Am J Respir Med. 2003;2:139–156.
   PubMedGoogle Scholar
• Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotrien pathway. N Engl J Med. 1999;340:197–206.
   PubMed Web of Science ®Google Scholar
• Noonan MJ, Chervinsky P, Brandon PM, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J. 1998;11:1232–1239.
   PubMed Web of Science ®Google Scholar
• Altman LC, Munk Z, Seltzer J, et al. A placebo-controlled, dose-ranging study of montelukast, acysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol. 1998;102:50–56.
   PubMed Web of Science ®Google Scholar
• Uematsu T, Nakano M, Kosuge K, Kanamaru M, Nakashima M. The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. Eur J Clin Pharmacol. 1993;44(4):361–364.
   Web of Science ®Google Scholar
• Burioka N, Miyata M, Endo M, et al. Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime transdermal beta2-adrenoceptor agonist tulobuterol chronotherapy. Chronobiol Int. 2005;22:383–390.
   PubMed Web of Science ®Google Scholar
• Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med. 2007;101:1895–1902.
   PubMed Web of Science ®Google Scholar
• Hozawa S, Haruta Y, Terada M, Yamakido M. Effects of the addition of Beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma. Allergol Int. 2009;58:509–518.
   PubMedGoogle Scholar
• Bogin RM, Ballard RD. Treatment of nocturnal asthma with pulsed-release albuterol. Chest. 1992;102:362–366.
   PubMed Web of Science ®Google Scholar
• Storms WW, Nathan RA, Bodman SF, et al. The effect of repeat action albuterol sulphate (Proventil Repetabs) in nocturnal symptoms of asthma. J Asthma. 1992;29:209–216.
   PubMed Web of Science ®Google Scholar
• Pedersen BK, Laursen LC, Gnosspelius Y, Faurschou P, Weeke B. Bambuterol: effects of a new anti-asthmatic drug. Eur J Clin Pharmacol. 1985;29:425–427.
   PubMed Web of Science ®Google Scholar
• Moore-Gillon J. Volmax (salbutamol CR 8 mg) in the management of nocturnal asthma: a placebo-controlled study. Eur Respir J. 1988;1:306s. [Abstract].
   PubMedGoogle Scholar
• Creemers JD. A multicenter comparative study of salbuterol controlled release (Volmax) and sustained-release theophylline (Theo-Dur) in the control of nocturnal asthma. Eur Respir J. 1988;1(Suppl 2):333s. [Abstract].
   Google Scholar
• Reinberg A, Guillet P, Gervais P, Ghata J, Vignaud D, Abulker C. One-month chronocorticotherapy (Dutimelan 8–15 mite): control of the asthma condition without adrenal suppression and circadian alteration. Chronobiologia. 1977;4:295–312.
   PubMedGoogle Scholar
• Leslie S. The Contin delivery system: dosing considerations. J Allergy Clin Immunol. 1986;78:768–773.
   PubMed Web of Science ®Google Scholar
• Shukla D, Chakraborty S, Mishra B. In vitro and in vivo evaluation of multi-layered pastilles for chronotherapeutic management of nocturnal asthma. Expert Opin Drug Deliv. 2012;9:9–18.
   PubMed Web of Science ®Google Scholar